<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00919451</url>
  </required_header>
  <id_info>
    <org_study_id>ITCRBY24-T1RB</org_study_id>
    <nct_id>NCT00919451</nct_id>
  </id_info>
  <brief_title>Ciclosporin in the Management of Steroid Resistant Type 1 Reactions in Leprosy</brief_title>
  <official_title>A Pilot Study Assessing the Efficacy and Safety of Ciclosporin as a Second -Line Drug in Patients With Type 1 Reactions Who Have Not Responded to a 12 Week Course of Prednisolone.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Homes and Hospitals of St Giles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alert Hospital, Ethiopia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Armauer Hansen Research Institute, Ethiopia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>London School of Hygiene and Tropical Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study 1B: Ciclosporin in the management of steroid resistant Type 1 Reactions in Leprosy

      Objective: A pilot study assessing the efficacy and safety of Ciclosporin as a second -line
      drug in patients with Type 1 Reactions who have not responded to a 12 week course of
      Prednisolone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>improvement in nerve function</measure>
    <time_frame>at 24 weeks and 32 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of adverse effects</measure>
    <time_frame>throughout 32 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin lesion inflammation improvement</measure>
    <time_frame>up to 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of improvement of reaction</measure>
    <time_frame>up to 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next reactional episode</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>extra prednisolone needed to control reaction</measure>
    <time_frame>up to 36 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Leprosy</condition>
  <arm_group>
    <arm_group_label>Ciclosporin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ciclosporin reducing regimen lasting 24 weeks (additional prednisolone given for the first four weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ciclosporin</intervention_name>
    <description>Ciclosporin 7.5mg/kg - reducing regimen over 24 weeks (additional prednisolone given for the first four weeks)</description>
    <arm_group_label>Ciclosporin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals with clinical evidence of Type 1 Reaction who have not responded to 3
             months Prednisolone Treatment

          -  Aged 18-65

          -  Weigh more than 30Kg

        Exclusion Criteria:

          -  Unwillingness to give informed consent

          -  Patients with severe active infections such as tuberculosis

          -  Pregnant or breastfeeding women (see Appendix II)

          -  Those with renal failure, abnormal renal function, hypertensive

          -  Patients taking thalidomide currently or within the last 3 months

          -  Patients not willing to return for follow-up

          -  Women of reproductive age not willing to use contraception for the duration of the
             study ( see Appendix II)

          -  HIV positive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diana NJ Lockwood, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>London SHTM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alert Hospital</name>
      <address>
        <city>Addis Abeba</city>
        <country>Ethiopia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ethiopia</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2009</study_first_submitted>
  <study_first_submitted_qc>June 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2009</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leprosy</keyword>
  <keyword>Type 1 Reaction</keyword>
  <keyword>Prednisolone</keyword>
  <keyword>Ciclosporin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leprosy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

